ID Analysts

Our seasoned team of analysts continually monitors investment opportunities around the world, to provide investors with the widest possible array of money-making ideas.

Analyst Articles

We’re holding three gold positions right now. The Barrick Gold (ABX) January 37.50 call option (ABX + AU) has moved up sharply and is rated a hold at this time. The Agnico-Eagle Mines January 65 call option (AEM + AM) is still out of the money and can be considered a buy. Likewise, our Gabriel Resources (GBU.TO, GBRFF),which is a long-term gold play is a buy its current price.   The late-season Hurricane Ida has caused an evacuation of personnel from oil and gas assets in the Gulf of Mexico and pushed crude oil above $80 a barrel. That has been good new for oil-related stocks, including Transocean (RIG). We don’t see a lasting impact from Ida for Transocean, but the move suggests the stock is now headed for the mid $90s and likely higher. Our Transocean January 95 call option (RIG + AS) is a buy at its current price.   Eli Lilly’s CEO said the other day that he favors mergers in the $1 billion to $2 billion range rather than larger deals. Its partner, Amylin Pharmaceuticals (AMLN), coincidentally falls into that category. Our recommendation of Amylin wasn’t predicated on a takeover, but such an announcement wouldn’t be the least bit surprising, especially from Lilly, which is an important stake in diabetes drugs. Another major driver for the stock would be FDA approval for an extended-release version of Byetta, which could come before year’s end. The Amylin Pharmaceuticals January 12.50 call option (AQM + AV) is a buy for new clients at the current price.   Read More

Stocks posted their worst showing last week in eight months. The action was dreadful with all sectors and market segments being clipped. Small caps fared the worst, dropping anywhere from 5 to more than 6 percent, depending the on the average you choose to examine. Read More

One addition to our holdings since the last Update was the purchase of the Agnico-Eagle Mines January 65 call option (AEM + AM). The stock, which was already down on soft gold prices, took a dive when investors were disappointed with the company’s quarterly results. The earnings miss was far from a disaster, however, and the company continues to expand at an admirable pace. The option is a buy at the current price as the stock isn’t likely to stay down for long.   Barrick Gold (ABX) should also rebound before long. Interviewed at a mining conference the other day, Jamie Sokalsky, the company’s chief financial officer, told Reuters the company had repurchased 1 million ounces of hedged gold in October and indicated that Barrick may lift its gold hedges sooner than previously believed. With the hedges removed, the stock should start to command higher valuations. The Barrick Gold (ABX) January 37.50 call option (ABX + AU) is also a buy at the current market price.   Ditto Gabriel Resources (GBU.TO, GBRFF), our longer-term gold play. New clients can buy the stock at its current price.   Our other resource play, the Transocean January 95 call option (RIG + AS) is a buy at its current price.   Read More

During the past week the stock market has shown numerous signs that the seven-month rally, which has carried shares to not only deeply overbought territory but to their highest valuations in years as well, is getting tired.   Read More

Transocean (RIG) bounced off support at the $86 level this morning. The stock may trade sideways for a time but high oil prices should bring investors to the shares in force. The Transocean January 95 call option (RIG + AS) is a buy at its current price.   Barrick Gold (ABX) has likewise slipped to support and should find buyers here. The Barrick Gold (ABX) January 37.50 call option (ABX + AU) is also a buy at the current market price.   We also like Gabriel Resources (GBU.TO, GBRFF) prospects going forward, although it’s a longer-term gold play. New clients can buy the stock here.   As with most everything, Amylin Pharmaceuticals (AMLN) has retrenched since our last update. The company reported better than expected results last week, but we’re waiting on a favorable ruling from the FDA on using Byetta as a monotherapy to really move the stock and/or progress on the use of the company’s drugs to fight obesity. The Amylin Pharmaceuticals January 12.50 call option (AQM + AV) is a buy for new clients.   Read More

The dollar continues to work its way lower, prompting people to shift more assets into riskier investments such as stocks. This is a trade that could persist for a time, and indeed, the Federal Reserve and the U.S. Read More

We made several changes earlier today. We added the American Express January 36 put option (ABZ + MD) in anticipation of the company disappointing shareholders, beginning with its earnings report due out on Thursday. Set a limit to pay more than $3.15 per contract.   We closed out the… Read More